Impact of Botulinum Toxin Use in Parkinson's Disease Patients: a Systematic Review
DOI:
https://doi.org/10.34024/rnc.2021.v29.11889Keywords:
Parkinson's disease, ; Botulinum Toxins Type A, Sialorrhea, Dystonia, TremorAbstract
Introduction. Botulinum Toxin (TxB) has been widely used to treat symptoms of Parkinson's disease (PD) and its efficacy and safety has been confirmed in several studies. Objective. To verify the impact of the use of botulinum toxin in patients with PD. Method. The search for scientific articles was conducted by two independent researchers in the MEDLINE (Pubmed) databases, LILACS, SciELO, SCOPUS, WEB OF SCIENCE and BIREME, without language and location restrictions, during the period from 2015 to 2020. For to complement and avoid risk bias, a search for gray literature was carried out on Google Scholar. The systematic review was conducted according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA). Studies that scored ≥ 6 points according to the qualitative scoring protocol proposed by Pithon et al. Results. 97 articles with potential for inclusion were retrieved, 4 of which answered the guiding question, which consisted of verifying the impact of using TxB in patients with PD. The selected articles reported the use of BTX to treat drooling, tremor and dystonia of the feet. The use of BTX has been shown to be effective in the long term to treat drooling, dystonia of the feet and limb tremor. Conclusion. The analyzes showed that BTX has a positive impact on PD patients, being a great ally in improving the quality of life of these patients, with few side effects, most of which are mild.
Metrics
References
Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-91. https://doi.org/10.1093/brain/119.2.585
Teive HA. Etiopatogenia da Doença de Parkinson. Rev Neurocienc 2005;13:201-14. https://doi.org/10.34024/rnc.2005.v13.8794
Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging 2010;27:295-310. https://doi.org/10.2165/11318330-000000000-00000
Andrade L, Barbosa ER, Cardoso F, Teive HAG. Doença de Parkinson: Estratégias atuais de tratamento. 4ª ed. São Paulo: Omnifarma, 2014.
Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatr Clin Neurosci 2002;14:223-36; discussion 222.
https://doi.org/10.1176/jnp.14.2.223
Cabreira V, Massano J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Med Port 2019;32:661-70.
http://dx.doi.org/10.20344/amp.11978
Correia MGS, Paixão AO, Jesus AVF, Silva FS, Messias GMS, Nunes TLGM, et al. Doença de Parkinson: uma desordem neurodegenerativa. CGCBS 2013;1:57-65.
https://periodicos.set.edu.br/cadernobiologicas/article/view/290
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93. https://doi.org/10.1016/j.neuro.2005.01.017
Colhado OCG, Boeing MO, Bornia L. Toxina botulínica no tratamento da dor. Rev Bras Anestesiol 2009;59:366-81. https://doi.org/10.1590/S0034-70942009000300013
Jocson A, Lew M. Use of botulinum toxin in Parkinson’s disease. Parkinsonism Relat Disord 2019;59:57-64.
http://dx.doi.org/10.1016/j.parkreldis.2018.12.002
Amantéa DV, Novaes AP, Campolongo GD, Barros TP. A Utilização da Toxina Botulínica tipo A na Dor e Disfunção Temporomandibular. J Bras Oclus ATM Dor Orof 2003;3:170-3. https://www.dtscience.com/wp-content/plugins/pdf-viewer-for-wordpress/web/viewer-shortcode.php?file=https://www.dtscience.com/wp-content/uploads/2015/10/A-Utiliza%C3%A7%C3%A3o-da-Toxina-Botul%C3%ADnica-tipo-A-na-Dor-e-Disfun%C3%A7%C3%A3o-Temporomandibular.pdf&settings=111101011&lang=en-US#page=&zoom=auto
Moher D, Shamseer L, Clarke M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. https://doi.org/10.1136/bmj.m2632
Pithon MM, Sant'anna LIDA, Baião FCS, Santos RL, Coqueiro RS, Maia LC. Assessment of the effectiveness of mouthwashes in reducing cariogenic biofilm in orthodontic patients: a systematic review. J Dent 2015;43:297-308. http://dx.doi.org/10.1016/j.jdent.2014.12.010
Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki Andrzej, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord 2020;70:23-30.
http://dx.doi.org/10.1016/j.parkreldis.2019.11.024
Alvarado-Gutiérrez AY, Franco JH, Villavicencio IS. Toxina botulínica tipo A en el tratamiento de sialorrea en pacientes con enfermedad de Parkinson. Arc Neurocienc 2015;20:174-81.
http://neurociencias.valoragregado.org/index.php/ADN/article/view/89/109
Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: A case series and a pilot study. J Rehabil Med 2016;48:559-62. http://dx.doi.org/10.2340/16501977-2094
Samotus O, Lee J, Jog M. Terapia de tremor de longo prazo para Parkinson e tremor essencial com injeções de toxina botulínica tipo A guiadas por sensor. PLoS One 2017;12:e0178670. http://dx.doi.org/10.1371/journal.pone.0178670
Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for parkinson's disease. Mov Disord 2009;24:635-46.
http://dx.doi.org/10.1002/mds.22260.
Kuiper MJ, Vrijenhoek L, Brandsma R, Lunsing RJ, Burger H, Eggibk H, et al. The Burke-Fahn-Marsden Dystonia Rating Scale is Age-Dependent in Healthy Children. Mov Disord Clin Pract 2016;3:580-6. http://dx.doi.org/10.1002/mdc3.12339.
Gómez-Caravaca MT, Cáceres-Redondo MT, Huertas-Fernández I, Vargas-González L, Carrillo F, Carballo M, et al. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. Neurol Sci 2015;36:275-9. http://dx.doi.org/10.1007/s10072-014-1950-y
Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012;27:219-26. http://dx.doi.org/10.1002/mds.23929
Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, et al. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial. Parkinsonism Relat Disord 2018;46:9-15. http://dx.doi.org/10.1016/j.parkreldis.2017.10.009
Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995;10:333-6.
http://dx.doi.org/10.1002/mds.870100317
Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. Can J Neurol Sci 2013;40:663-9. http://dx.doi.org/10.1017/s031716710001489x
Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. Mayo Clin Proc 2017;92:1359-67.
http://dx.doi.org/10.1016/j.mayocp.2017.06.010
Sposito MM. Toxina Botulínica do Tipo A: Mecanismos de ação. Acta Fisiátr 2009;16:25-37. http://dx.doi.org/10.11606/issn.2317-0190.v16i1a103037
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Daniely Hackbarth de Souza, Laura Faustino Gonçalves, Cláudia Tiemi Mituuti, Karina Mary de Paiva , Patricia Haas
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Accepted 2021-08-23
Published 2021-09-13
